MedTrace Logo

Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill

NCT04358809 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2020-12-22

No results posted yet for this study

Summary

This is a randomized, double blind, two arms, placebo controlled, clinical trial to study to evaluate the the safety and efficacy of Mycobacterium w in combination with standard of care versus placebo with standard of care for preventing the progression of COVID-19 disease and for reduction in transfer to ICU in COVID-19 infected patients admitted to the hospital.

Conditions

Interventions

DRUG

Suspension of heat killed (autoclaved) Mycobacterium w

Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19

OTHER

Placebo

Placebo along with Standard of care (SOC) treatment for COVID-19

Sponsors & Collaborators

  • Council of Scientific and Industrial Research, India

    collaborator OTHER_GOV

  • Cadila Pharnmaceuticals

    lead INDUSTRY

Principal Investigators

  • Sanjay Patel, MBBS · Cadila Pharmaceuticals Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2021-02-28
Completion
2021-04-30

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04358809 on ClinicalTrials.gov